Cell Growth & Differentiation, Vol 6, Issue 6 769-779, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Coexpression of the c-kit and stem cell factor genes in breast carcinomas

SJ Hines, C Organ, MJ Kornstein and GW Krystal
Department of Medicine, Medical College of Virginia, Richmond 23249, USA.

Expression of the c-kit tyrosine kinase growth factor receptor has been reported in some breast tumors; however, no data exist concerning expression of its ligand, stem cell factor. The aim of this study was to determine how frequently the c-kit and stem cell factor genes were coexpressed in breast tumors and tumor-derived cell lines and to determine whether coexpression of c-kit and stem cell factor could result in growth stimulation of breast tumor cells. Expression of the c-kit and stem cell factor genes in tissue specimens and cell lines was determined using an RNase protection assay, with confirmation of c-kit protein expression by immunohistochemistry and Western blotting in tumor tissue and cell lines, respectively. Of 11 tumor specimens studied, 9 expressed variable but detectable quantities of c-kit; 7 of 13 tumor-derived cell lines also expressed c-kit. All tumor specimens and cell lines expressed detectable stem cell factor mRNA, suggesting that an autocrine growth loop could exist in the majority of breast carcinomas. To determine the biological effects of coexpression of c-kit and stem cell factor, the MCF-7 cell line, which expresses only stem cell factor, was transfected with a c-kit expression vector. Coexpression of c-kit and stem cell factor in MCF-7 cells resulted in an enhanced growth rate and cloning efficiency but not a loss of the dependence of this cell line upon estrogen. Analysis of subclones expressing different amounts of c-kit protein revealed that, although they all showed enhanced growth relative to control transfectants in serum-free medium containing IGF-1, only the highest c-kit expressor responded with additional growth to exogenous soluble stem cell factor. However, all c-kit-expressing clones, but not control clones, showed growth inhibition when exposed to a blocking anti-c-kit antibody. This blocking antibody also significantly inhibited the growth of the established ZR75-1 cell line in serum-free medium containing IGF-1. Taken together, these data suggest that coexpression of stem cell factor and c-kit could be responsible for growth deregulation in a significant number of breast carcinomas.

This article has been cited by other articles:

				R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF]

				A. Catalano, S. Rodilossi, M. R. Rippo, P. Caprari, and A. Procopio Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells J. Biol. Chem., November 5, 2004; 279(45): 46706 - 46714. [Abstract] [Full Text] [PDF]

				L. Boldrini, S. Ursino, S. Gisfredi, P. Faviana, V. Donati, T. Camacci, M. Lucchi, A. Mussi, F. Basolo, R. Pingitore, et al. Expression and Mutational Status of c-kit in Small-Cell Lung Cancer: Prognostic Relevance Clin. Cancer Res., June 15, 2004; 10(12): 4101 - 4108. [Abstract] [Full Text] [PDF]

				T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, B. Weinkauf, J. Duyster, C. Peschel, C. J. Kirkpatrick, M. Theobald, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia Blood, May 15, 2004; 103(10): 3644 - 3654. [Abstract] [Full Text] [PDF]

				T. J. Abrams, L. J. Murray, E. Pesenti, V. Walker Holway, T. Colombo, L. B. Lee, J. M. Cherrington, and N. K. Pryer Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer Mol. Cancer Ther., October 1, 2003; 2(10): 1011 - 1021. [Abstract] [Full Text]

				M. S. Merchant, C.-W. Woo, C. L. Mackall, and C. J. Thiele Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo Activity J Natl Cancer Inst, November 20, 2002; 94(22): 1673 - 1679. [Abstract] [Full Text] [PDF]

				J. Perez-Losada, M. Sanchez-Martin, A. Rodriguez-Garcia, M. L. Sanchez, A. Orfao, T. Flores, and I. Sanchez-Garcia Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway Blood, July 30, 2002; 100(4): 1274 - 1286. [Abstract] [Full Text] [PDF]

				S. Maddens, A. Charruyer, I. Plo, P. Dubreuil, S. Berger, B. Salles, G. Laurent, and J.-P. Jaffrezou Kit signaling inhibits the sphingomyelin-ceramide pathway through PLCgamma 1: implication in stem cell factor radioprotective effect Blood, July 30, 2002; 100(4): 1294 - 1301. [Abstract] [Full Text] [PDF]

				A. V. Moses, M. A. Jarvis, C. Raggo, Y. C. Bell, R. Ruhl, B. G. M. Luukkonen, D. J. Griffith, C. L. Wait, B. J. Druker, M. C. Heinrich, et al. Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells J. Virol., July 17, 2002; 76(16): 8383 - 8399. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies J. Clin. Oncol., March 15, 2002; 20(6): 1692 - 1703. [Abstract] [Full Text] [PDF]

				G. W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, L. Sun, G. McMahon, and K. E. Lipson Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells Cancer Res., May 1, 2001; 61(9): 3660 - 3668. [Abstract] [Full Text]

				E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, and N. B. Lydon Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 139 - 145. [Abstract] [Full Text]

				J. A. Parrott, R. Mosher, G. Kim, and M. K. Skinner Autocrine Interactions of Keratinocyte Growth Factor, Hepatocyte Growth Factor, and Kit-Ligand in the Regulation of Normal Ovarian Surface Epithelial Cells Endocrinology, July 1, 2000; 141(7): 2532 - 2539. [Abstract] [Full Text] [PDF]

				Q. Tian, H. F. Frierson Jr., G. W. Krystal, and C. A. Moskaluk Activating c-kit Gene Mutations in Human Germ Cell Tumors Am. J. Pathol., June 1, 1999; 154(6): 1643 - 1647. [Abstract] [Full Text] [PDF]

				N. R. Leslie, J. O'Prey, C. Bartholomew, and P. R. Harrison An Activating Mutation in the Kit Receptor Abolishes the Stroma Requirement for Growth of ELM Erythroleukemia Cells, But Does Not Prevent Their Differentiation in Response to Erythropoietin Blood, December 15, 1998; 92(12): 4798 - 4807. [Abstract] [Full Text] [PDF]

				G. H. Park, H. K. Plummer III, and G. W. Krystal Selective Sp1 Binding Is Critical for Maximal Activity of the Human c-kit Promoter Blood, December 1, 1998; 92(11): 4138 - 4149. [Abstract] [Full Text] [PDF]

				E. Ricotti, F. Fagioli, E. Garelli, C. Linari, N. Crescenzio, A. L. Horenstein, P. Pistamiglio, S. Vai, M. Berger, L. C. diMontezemolo, et al. c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells Blood, April 1, 1998; 91(7): 2397 - 2405. [Abstract] [Full Text] [PDF]

				M. Sattler, R. Salgia, G. Shrikhande, S. Verma, E. Pisick, K. V.S. Prasad, and J. D. Griffin Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL J. Biol. Chem., April 11, 1997; 272(15): 10248 - 10253. [Abstract] [Full Text] [PDF]